Anacura acquires spin-off from Ghent University
Anacura adding multi-omics for drug discovery and diagnostics to its services
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
Anacura CEO Griet Nuytinck says: “The acquisition of OHMX.bio is the next step in anacura’s aim to remain a frontrunner in innovative healthcare services, complementing ongoing initiatives within our existing business units. With the acquisition, we bring in a company with deep scientific expertise that shares our key values, enabling us to provide an even stronger service offering to the biotech community in Belgium and beyond.”
Established in 2019 as a Ghent University spin-off, OHMX.bio operates as a premier study design company, specializing in cutting-edge -omics technologies for discovery and (pre)clinical studies. The company combines multi-omic technologies, such as next-generation sequencing, in combination with advanced bio-informatics to speed up the discovery process and quality control of biologics and advanced therapy medicinal products (ATMPs) such asmRNA vaccines and CAR-T cells.
OHMX.bio CEO/CSO Gerben Menschaert adds: “Our activities complement the current service offering within the anacura group and, importantly, we share the same values, mission and drive for quality, scientific excellence, and a tailored personal approach.”
Menschaert is one of the co-founders of OHMX.bio and is a professor at the Lab of Bioinformatics and Computational Genomics at Ghent University.
“OHMX.bio joining the anacura family is a future proof move for both parties,” he says, “It will allow OHMX.bio to expand its portfolio and tap into new markets, Additionally, it strengthens anacura’s offering of innovative technologies. Collectively, we solidify anacura’s position as a one-stop shop for clients and market leader in the Ghent Biotech ecosystem.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
